Cambridge Innovation Capital
VC Fund
Cambridge, United Kingdom
Cambridge Innovation Capital is a VC fund in Cambridge focused on Biotechnology and Health Care. Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.
- Total investments:
- 118
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $332M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Cambridge Innovation Capital invests in
Stages Cambridge Innovation Capital invests in
Countries Cambridge Innovation Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Seed
- $2M–$31M
- Series A
- $2.6M–$73M
- Series B
- $8.2M–$61M
Investment Focus
Industry
- Biotechnology 24 (20%)
- Health Care 14 (12%)
- Medical 11 (9%)
- Therapeutics 11 (9%)
- Software 10 (8%)
Stage
- Series A 27 (23%)
- Series B 23 (19%)
- Seed 17 (14%)
- Series C 7 (6%)
- Funding Round 7 (6%)
Country
- United Kingdom 43 (36%)
- United States 4 (3%)
- Ireland 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anne Horgan
Partner
|
Partner | Total investments: 3 | Find email | |
Damian Crowther
Entrepreneur In Residence
|
Entrepreneur In Residence | Total investments: 0 | Find email | |
Edward Benthall
Chairman
|
Chairman | Total investments: 2 | Find email | |
Humphrey Battcock
Independent Non-executive Director
|
Independent Non-executive Director | Total investments: 0 | Find email | |
Ian Jauncey
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | ||
| Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures. | $12.7M / Seed / Apr 07, 2026 | ||
| Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M / Series A / Mar 24, 2026 | ||
|
BeyondMath
|
AI-first approach to simulating the physical world | $10M / Seed / Feb 25, 2026 | |
| T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. . | $32M / Series A / Nov 13, 2025 | ||
| Sortera Bio operates as a biotechnology company. Sortera is committed to providing revolutionary solutions in biologics discovery. | $10.2M / Pre-Seed / Jun 05, 2025 | ||
| TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M / Seed / Mar 05, 2025 | ||
| Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany. | $30M / Series A / Feb 07, 2025 | ||
| Forefront RF is a fabless semiconductor company. | $20.8M / Series A / Nov 07, 2024 | ||
| Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M / Seed / Oct 24, 2024 | ||
| See all 118 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Cambridge Innovation Capital invest in?
Cambridge Innovation Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 118 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Cambridge Innovation Capital's check size?
Cambridge Innovation Capital typically joins rounds of $2M–$31M at Seed, $2.6M–$73M at Series A and $8.2M–$61M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cambridge Innovation Capital participates in.
How do I contact Cambridge Innovation Capital?
Public channels for Cambridge Innovation Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cambridge Innovation Capital?
The team at Cambridge Innovation Capital includes Anne Horgan (Partner), Damian Crowther (Entrepreneur In Residence) and Edward Benthall (Chairman), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
